Home > News > 206/Aetiology and efficacy of atrial fibrillation ablation in young adults
Atrial Fibrillation
Read Time: 2 mins

206/Aetiology and efficacy of atrial fibrillation ablation in young adults

Published Online: October 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr206
Authors: RY Zhang (Presenting Author) – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; IT Fazmin – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; A Porto – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; K Divulwewa – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; A Reddy – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; J Gonzalez-Panizo – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; B di Nubila – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; MF Mausa – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; S Agarwal – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; D Begley – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; S Fynn – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; A Grace – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK; P Heck – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; G Mellor – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; M Virdee – Royal Papworth Hospitals NHS foundation trust, Cambridge, UK; CA Martin – Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK
Quick Links:
Article
Article Information
Article:

Introduction: Little is known regarding the aetiology or outcome of atrial fibrillation (AF) occurring in young adults. This retrospective analysis was performed to explore the demographics and efficacy of AF ablation in this population.

Methods: Patients were included who had undergone ≥1 AF ablation under the age of 40 between 2006–18. Recurrence, defined as return of either documented AF or previous symptoms for >30 s, was assessed. Initial exploratory co-variates were included in a univariate analysis and those terms with P-value of <0.1 were then used to generate a Cox proportional-hazards multivariate model.

Results: One-hundred-and-twenty-four patients (33.6 ± 4.7 years, 77% men), initially presenting with paroxysmal AF (pAF; n=97) or persistent AF (n=27), underwent 175 AF ablation procedures. 22.6% (n = 28) also had atrial flutter. Time from symptom onset to first ablation was 49.3 ± 45.1 months. Relevant cardiovascular-related demographics were analysed: hypertension in 8.9% (n=11); diabetes in 1.6% (n=2); positive family history of AF in 12.9% (n=16); and family history of sudden cardiac death in 2.4% (n=3). Mean CHA2DS2-VASc score was 0.35. Of those patients with documented echocardiogram imaging (n=91), 26.4% (n=24) had LA dilatation and 6.6% (n=6) had LV dysfunction. Patients with LA dilatation underwent more ablations (2.1 ± 1.1) compared to controls (1.4 ± 0.7; p<0.001).

Ablation strategy was pulmonary vein isolation (PVI) only in 67.2% (n=119), with additional ablation in the remaining: roof line in 18.9% (n=33); cavotricuspid isthmus line in 13.1% (n=23); mitral isthmus line in 2.3% (n=4); superior vena cava isolation in 2.3% (n=4); complex fractionated atrial electrograms in 14.9% (n=26). Mean procedure time was 155 ± 41 min, mean ablation time was 1657 ± 991 s and mean fluoroscopy time was 32.6 ± 23.4 min. General anaesthesia was used in 43.4% (n=76). Sinus rhythm was restored during ablation in 54.1% of persistent AF cases. Complications included femoral haematoma (n=2), tamponade (n=1) and pulmonary vein stenosis (n=2). Eighty-four percent of patients were on antiarrhythmics pre-procedure: 48.5% on beta blockers, 44.2% on flecainide/propafenone, 8.6% on sotalol, 6.7% on a calcium channel blocker, 6.1% on amiodarone/dronedarone.

At least 90 days of follow-up was available for 150 procedures performed for pAF (n=115) and persistent AF (n=35). For pAF, overall recurrence was 61.4% for first ablations and 58.3% overall. Recurrence was 62.9% (n=22) for persistent AF.

Factors significantly associated with increased AF recurrence in univariate analysis were: male gender (hazard ratio [HR] 1.9, 95% confidence interval [CI]: 1.0–3.6, p=0.042), family history of sudden cardiac death (HR 4.3, CI: 1.0–18.1, p=0.046) and enlarged LA size (HR 2.2, CI: 1.3–3.6, p=0.002). In multivariate analysis, the only significant predictor of poor outcome was enlarged LA size (HR 2.2, CI: 1.3–3.7, p=0.004).

Conclusions: Young patients with AF may have structurally abnormal hearts, and therefore do not only present with lone AF. Despite this, AF ablation is effective in young adults. LA size may be used as a predictor for success. Surveillance imaging may be useful to detect future structural change, which will be the subject of future prospective studies.

Article Information:

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72